Explore 3 Stock Ideas & Industry Insights Download Free Report

News

McDonald's Shares Surge 4% as Q1 Earnings Beat and Executive Hire Fuel Rally

• McDonald's (NYSE:MCD) shares surged 4.16 percent to 280.63 dollars in heavy trading, with volume well above its daily average.

Vinay Lochav | 02 July 2026

Genuine Parts Surges 13% on Report of O'Reilly Cash Bid for Auto Parts Unit

• Genuine Parts Company (NYSE:GPC) shares surged 12.92 percent to 132.57 dollars after a report that O'Reilly Automotive submitted a cash bid for its automotive parts business.

Vinay Lochav | 02 July 2026

Appeals Court Lifts Order Requiring Reinstallation of Removed National Park Exhibits

• A three-judge panel of the 1st U.S. Circuit Court of Appeals put on hold a judge's order requiring reinstallation of removed national park exhibits.

Vinay Lochav | 02 July 2026

Costco Wholesale (NASDAQ:COST) Closes Up 3% Today Alongside Broader Defensive Rally

• The June jobs report showed just 57,000 payrolls added versus roughly 110,000 expected.

Vinay Lochav | 02 July 2026

ProPetro Holding (NYSE:PUMP) Falls 10% Today as Oil Price Weakness Weighs on Oilfield Services

• Crude prices dropped roughly 1-4% on the day amid cautious optimism around U.S.-Iran peace talks in Doha.

Vinay Lochav | 02 July 2026

Pancreatic Cancer Drug Race 2026: Elicio Therapeutics (NASDAQ: ELTX) Phase 1 Vaccine and Revolution Medicines (NASDAQ: RVMD) Phase 3 RAS Inhibitor Target Same Disease

• Two Very Different Scientific Approaches: Elicio's ELI-002 7P is an immune-activating cancer vaccine while Revolution Medicines' daraxonrasib is a direct small molecule RAS inhibitor targeting the same disease.

Vinay Lochav | 02 July 2026

Radiopharmaceutical Oncology 2026: Telix Pharmaceuticals (NASDAQ: TLX) and Molecular Partners (NASDAQ: MOLN) Advance Competing Nuclear Medicine Programs

• Two Distinct Isotope Approaches: Telix uses lutetium-177 (beta emitter) in prostate cancer while Molecular Partners employs lead-212 (alpha emitter) in small cell lung cancer.

Vinay Lochav | 02 July 2026

ESC Congress 2026 Late-Breaking Preview: Why Tenax Therapeutics' (NASDAQ: TENX) Oral Levosimendan Data Could Reshape Heart Failure Guidelines

• Only Oral Formulation of Levosimendan in Phase 3: If successful, oral levosimendan would be the first oral formulation of an established IV heart failure inotrope to reach approval.

Vinay Lochav | 02 July 2026

Small Cap Healthcare Roundup 2026: Eight Companies Navigate FDA Clearances, Dilutive Raises, Nasdaq Notices, and IP Milestones in One Session

• Eight Companies With Simultaneous Catalysts: A single session produced FDA clearances, clinical data, capital raises, compliance notices, buybacks, reverse splits, patent grants, and biocompatibility results across eight companies.

Vinay Lochav | 02 July 2026

Argan (NYSE:AGX) Drops 8% Today as Investors Book Profits After 144% Year-to-Date Surge

• The pullback follows a remarkable year-to-date surge of over 144%.

Vinay Lochav | 02 July 2026
Support

Hi! How can we help you today?

Loading…